Global review of transthyretin amyloidosis shows wide disparities among regions
Despite treatment advancements, ATTR remains poorly understood, with significant variations in prevalence and survival rates across regions.
Despite treatment advancements, ATTR remains poorly understood, with significant variations in prevalence and survival rates across regions.
Patients with a combination of ATTR-CM and aortic stenosis had worse clinical outcomes compared with those with aortic stenosis alone.
The stroke volume index appears to have greater prognostic accuracy for mortality in ATTR-CM than traditional echocardiographic indexes.
A study found that patients with ATTR-CM who underwent heart transplantation experienced survival rates similar to patients without it.
Patients with asymptomatic ATTR-CM and high cardiac uptake could benefit from disease-modifying treatment, according to a new study.
Emerging therapies — including TTR stabilizers, silencers and depleters — offer new hope for managing ATTR-CM.
A case report emphasized the challenges of diagnosing transthyretin amyloid cardiomyopathy (ATTR-CM) and the need for early intervention.
Researchers looked at a patient with rheumatoid arthritis who developed transthyretin amyloid cardiomyopathy-mediated heart failure.
Advances in radionuclide imaging and emerging therapies have improved diagnosis and management of ATTR-CM.
Researchers identified factors that can accurately predict patients with wild-type ATTR-CM who are at high risk of early death.